Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals, Inc. announced that the US FDA has accepted an investigational new drug (IND) application for KPI-012, a human MSC secretome, initially in development for the treatment of persistent corneal epithelial defect (PCED).